Programme celebrates partnership excellence

Acalabrutinib combinations approved for CLL and MCL

First patient enrolled in Agni-01 expansion

Postmenopausal study highlights oral anabolic potential

Decision expands options for eligible patients

Study evaluates tri‑specific T cell engager LBL‑051

Designation supports accelerated access for investigational antibody

EC expands use to protect youngest children

New therapy aims to tackle antibiotic resistance

Regulators assess PB016 vedolizumab biosimilar applications